Drug Profile
Research programme: antifolates - Chelsea Therapeutics
Alternative Names: CH-2308; CH-4446Latest Information Update: 18 Jan 2011
Price :
$50
*
At a glance
- Originator University of South Alabama
- Developer Chelsea Therapeutics
- Class
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2007 Antifolate compounds are available for licensing worldwide (http://chelseatherapeutics.com/contact.html)
- 22 Jun 2005 Early research in Cancer in USA (PO)